In order to determine HCV reinfection rates following sustained virologic response (SVR) in the overall population as well as in PWID, the study authors analyzed data obtained from a population-based study that included >1.7 million people that were tested for HCV.
The study included 17,149,480 patients obtained from 2 national laboratory datasets who were screened between 2013 and 2016 based on an AB test.
ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) was utilized to identify all patients who received HCV treatment for at least 7 weeks as well as a propensity-score matched group who did not receive treatment.
In order to determine the association between CHC and parkinsonism, the study authors utilized the National Health Insurance Research Database in Taiwan to identify CHC patients between 2004 and 2012.
The retrospective study aimed to determine the risk of incident, or de novo, HCC following different regimens of antiviral therapy.
The review analyzed 168 patients treated with an oral DAA at a single center from 2015 to 2017.
The study utilized data from the Chronic Hepatitis Cohort Study, an observational cohort study, to assess demographic and clinical characteristics associated with DAA use.
The study compared US administrative claims data of HCV patients with ≥12 weeks of dispensed DAA therapy (N=17,848) to untreated HCV patients with follow-up data (N=108,350).
Glecaprevir/Pibrentasvir 8-Week Regimen Evaluated in Treatment-Naïve HCV Patients With Compensated Cirrhosis
In EXPEDITION-8, 280 treatment-naïve HCV patients (genotypes 1, 2, 4, 5, and 6) with compensated cirrhosis were treated with Mavyret for 8-weeks; the primary efficacy measure was SVR12 rate.
The study aimed to determine whether direct-acting antiviral therapy reduced fibrosis and assessed whether any predictors of treatment failure existed at 1-year follow-up.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Topical Antibacterial Agent Effective for Treatment of Impetigo
- Novel H pylori Eradication Therapy Effective in Phase 3 Trial
- Polymyxin B Hemoperfusion Does Not Change Mortality Rate in Septic Shock
- Addiction Medicine Consultation Improves Antibiotic Compliance in Patients with Opioid Use Disorders
- Guideline Adoption for Childhood Community-Acquired Pneumonia
- High Sensitivity, Specificity for Chlamydia Point-of-Care Test
- Infections Linked to Increased Later Risk for Mental Disorders
- Glecaprevir/Pibrentasvir Effective in Hepatitis C Genotypes 5 and 6
- Invasive Pneumococcal Disease Risk Higher in Premature Infants
- Management Mycobacterium chimaera Outbreak From Heater-Cooler Units